The latest price target for Q32 Bio (NASDAQ:QTTB) was reported by BMO Capital on December 12, 2024. The analyst firm set a price target for $22.00 expecting QTTB to rise to within 12 months (a possible 564.65% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Q32 Bio (NASDAQ:QTTB) was provided by BMO Capital, and Q32 Bio maintained their outperform rating.

There is no last upgrade for Q32 Bio

The last downgrade for Q32 Bio Inc happened on December 12, 2024 when Guggenheim changed their price target from N/A to N/A for Q32 Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Q32 Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Q32 Bio was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Q32 Bio (QTTB) rating was a maintained with a price target of $64.00 to $22.00. The current price Q32 Bio (QTTB) is trading at is $3.31, which is out of the analyst’s predicted range.